A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD
← catalyst calendarNCT06843408 · readout in 140 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
32actual
Sites
9
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-25 | actual | When the study began enrolling |
| Primary completion | 2027-01-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-07-20 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Graft-versus-host-disease
Intervention
- Drug: INCA034176 — also filed as Axatilimab
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with Treatment-emergent Adverse Events (TEAEs)
measured Up to 2 years and 30 days
Objective Response in the First 6 Cycles
measured Up to Cycle 7 (Day 169)
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed